# Owkin

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/owkin

- Industry: Software
- Headquarters: New York, US
- Website: www.owkin.com
- Total disclosed funding: $61M
- Latest round: Series A (Jun 30, 2020)
- Investors on record: 10

## About

Owkin, Inc., based in the US, harnesses artificial intelligence to advance biomedical research, drug discovery, and diagnostics, offering innovative AI platforms that drive insights for clinical applications.Owkin, Inc. is a biotechnology firm founded in 2016 in New York, US, specializing in the use of AI for drug development and biomedical research. The company was co-founded by Thomas Clozel, Gilles Wainrib, and Marie-Anne G., and has raised a total of EUR 33.00 mn through funding rounds, with the latest being in March 2023 from investor Bpifrance Investissement. Owkin has engaged in 9 deals to date, focusing on enhancing precision pathology and biomarker discovery through AI-driven solutions.Owkin specializes in advanced agentic AI platforms designed to facilitate breakthroughs in biomedical research, drug discovery, and diagnostics. The company's core offerings include Owkin K, an agentic AI platform that integrates high-quality multimodal data to generate insights and support decision-making across research teams. Additionally, Owkin has developed OKN4395, a selective triple inhibitor currently in Phase 1 trials, which exemplifies their commitment to leveraging AI throughout the drug development process. Their solutions cater to a diverse clientele, including academic research institutions and pharmaceutical companies, focused on enhancing precision pathology and biomarker discovery. Owkin operates in various geographical markets, notably in North America and Europe, where they aim to address complex biological challenges and improve patient outcomes.Owkin generates revenue through a combination of partnerships with pharmaceutical companies and academic institutions, providing access to their AI-driven tools and technologies. Their business model includes subscriptions to the Owkin K platform, through which clients can access multimodal data and AI applications for research and clinical development. Additionally, they offer digital pathology solutions that support pathologists in screening biomarkers and predicting patient outcomes, which are essential in clinical trial settings. Revenue from these services may be driven by institutional contracts or licensing agreements that facilitate the integration of Owkin's technologies into existing workflows. The company’s flagship products, such as their digital pathology diagnostics and AI biomarker discovery tools, are pivotal in their offerings to clients within the healthcare sector.In March 2023, Owkin, Inc. raised EUR 33.00 mn to support its strategy of developing at least 15 AI-based tools aimed at improving cancer diagnosis, discovering new treatment biomarkers, and predicting patient outcomes in hospitals across France. The company plans to expand its AI applications into new markets, particularly focusing on the healthcare landscape in France, driving innovation in cancer care and enhancing diagnostic capabilities.

## Funding rounds

- Series A, Jun 30, 2020, $18M — Bpifrance Investissement, Mubadala Capital
- Series A, May 8, 2020, $25M — Eight Roads Ventures, F-Prime Capital, Cathay Capital, GV, Bpifrance Investissement, MACSF
- Series A, May 23, 2018, $5M — GV
- Series A, Jan 16, 2018, $11M — Cathay Capital, Plug and Play, Frst Capital, NJF Capital
- Seed, Oct 30, 2016, $2.1M — NJF Capital

## Investors

- NJF Capital (https://capitalatlas.ai/funds/njf-capital) — Seed, Series A
- Cathay Capital — Series A
- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Series A
- Frst Capital (https://capitalatlas.ai/funds/frst-capital) — Series A
- GV (https://capitalatlas.ai/funds/gv) — Series A
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A
- MACSF — Series A
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series A